The healthcare technology sector continues to evolve as companies introduce solutions designed to improve clinical precision, efficiency, and patient outcomes. One of the latest developments comes from Milestone Scientific Inc., which has announced the launch of its CompuFlo® Advisor Program. The initiative is aimed at accelerating commercial adoption of the company’s technology while strengthening reimbursement pathways across key U.S. healthcare markets.
Understanding the CompuFlo Technology:
Milestone Scientific is known for developing computerized drug delivery instruments designed to make injections more precise and controlled. Its CompuFlo Epidural System uses dynamic pressure sensing technology to help physicians accurately identify the epidural space during procedures. This real-time feedback can improve procedural accuracy and reduce complications compared with traditional methods.
The system has gained increasing attention among pain management and anesthesia specialists who are seeking more reliable tools for spinal injections and epidural procedures. By improving placement accuracy and consistency, the technology aims to enhance patient safety while supporting better clinical outcomes.
Launch of the CompuFlo Advisor Program:
The newly announced CompuFlo Advisor Program represents a strategic step by the company to expand adoption of its technology. The program officially began on February 1, 2026, and focuses on high-volume interventional pain and anesthesia practices in selected Medicare Administrative Contractor (MAC) jurisdictions.
The initial rollout targets several important healthcare regions, including Novitas, First Coast, Noridian, and Palmetto jurisdictions. These areas were chosen as the first phase of a broader strategy that could eventually expand nationwide. By focusing on key markets first, the company hopes to demonstrate the clinical and economic value of the healthcare technology while building momentum for wider adoption across the United States.
Supporting Physicians and Improving Reimbursement:
A major objective of the Advisor Program is to support physicians through the reimbursement process and increase utilization of the CompuFlo system. Milestone Scientific has built a structured support infrastructure designed to guide healthcare providers in documentation, claims management, and payer communication.
The company has engaged experienced reimbursement specialists and consultants to help physicians navigate billing procedures and ensure accurate submissions. This includes real-time claims assistance and advisory services aimed at simplifying the administrative burden for healthcare providers. Such support is intended to encourage clinicians to integrate the technology into routine practice while strengthening the economic case for its use.
Generating Clinical Data to Strengthen Market Adoption:
Another key goal of the program is to generate a strong body of clinical evidence supporting the use of the CompuFlo system. Milestone Scientific plans to work with key opinion leaders to produce between 1,000 and 2,000 clinical case submissions during the initial six-month phase of the program.
This data will be important for demonstrating the effectiveness and value of the technology to both regulators and healthcare payers. The company is particularly focused on supporting the transition of CPT code 0777T from Category III status to Category I, which could improve reimbursement stability and encourage broader adoption. If successful, this transition would significantly enhance the long-term commercial outlook for the technology.
Building a Scalable Commercial Ecosystem:
Milestone Scientific is positioning the Advisor Program as more than just a pilot initiative. The company has developed a scalable commercial infrastructure designed to support long-term growth and national expansion. This includes specialized consultants, provider support systems, and a structured engagement model with physicians and healthcare organizations. According to company leadership, the goal is to move beyond simply placing devices and instead create a comprehensive ecosystem that supports utilization and recurring revenue. Such an approach reflects a broader trend in the medical device industry, where companies increasingly focus on service models, training, and reimbursement strategies alongside product innovation.
Potential Impact on the Pain Management Market:
The pain management sector represents a significant opportunity for technologies that improve procedural accuracy and patient safety. Epidural injections are widely used in pain treatment and anesthesia, but they can present challenges for physicians due to anatomical variations and the need for precise needle placement.
Technologies like CompuFlo aim to address these challenges by providing objective guidance during procedures. If adoption expands across the targeted MAC jurisdictions and eventually nationwide, the technology could influence how epidural procedures are performed in the future. Healthcare providers, insurers, and policymakers are all increasingly interested in solutions that improve outcomes while reducing complications and costs.
Future Expansion Plans:
While the program initially focuses on selected jurisdictions, Milestone Scientific has indicated that it plans to expand the initiative across additional Medicare regions over time. The phased rollout strategy allows the company to refine its approach while building strong evidence and operational infrastructure.
As the program grows, the company expects increased utilization of the CompuFlo system, improved reimbursement pathways, and broader clinical awareness among healthcare professionals. This combination of clinical validation and commercial support could play an important role in establishing the technology as a standard tool in interventional pain management.
Conclusion:
The launch of the CompuFlo Advisor Program marks an important milestone for Milestone Scientific as it works to accelerate the adoption of its precision injection technology. By focusing on physician support, reimbursement optimization, and clinical evidence generation, the company is taking a comprehensive approach to expanding its presence in the healthcare market.
If the program succeeds in demonstrating strong clinical outcomes and achieving improved reimbursement status, it could significantly boost the adoption of the CompuFlo system across the United States. More broadly, the initiative highlights how medical technology companies are combining innovation, data, and strategic partnerships to transform patient care and modernize clinical procedures.
Source - Globe Newswire
